Table 3.
Assessment of liver fibrosis in the study participants using non-invasive screening tools.
| Variable Mean (95% CI) |
with T2DM (n = 34) |
without T2DM (n = 72) |
p-Value |
|---|---|---|---|
| Liver Enzymes | |||
| ALT (IU/L) | 35.3 (26.5, 44.1) | 36.1 (31.1, 41.0) | 0.392 |
| AST (IU/L) | 28.9 (21.6, 36.2) | 25.8 (22.8, 28.8) | 0.759 |
| GGT (IU/L) | 54.2 (40.2, 68.2) | 44.1 (36.9, 51.4) | 0.311 |
| Two-Dimensional (2D) Shear Wave Elastography | |||
| EQI Median (kPa) | 5.0 (4.5, 5.6) | 4.8 (4.5, 5.0) | 0.697 |
| Liver Fibrosis Assessment Scores | |||
| FIB-4 index | 1.0 (0.8, 1.2) | 0.8 (0.7, 0.9) | 0.016 |
| APRI | 0.3 (0.2, 0.4) | 0.3 (0.2, 0.3) | 0.672 |
| NFS | 1.5 (1.0, 1.9) | 0.4 (0.0, 0.8) | <0.001 |
| FAP index | −1.2 (−1.6, −0.8) | −3.0 (−3.4, −2.7) | <0.001 |
ALT: alanine aminotransferase; AST: aspartate aminotransferase; APRI: AST-to-platelet ratio index; EQI: ElastQ Imaging; FAP: fibroblast activation protein; FIB-4: Fibrosis-4; GGT: gamma-glutamyl transferase; NFS: NAFLD (non-alcoholic fatty liver disease) fibrosis score; T2DM: type 2 diabetes.